

## Peer Review File

Article Information: <https://dx.doi.org/10.21037/tcr-23-1117>

### Reviewer Comments

The editorial is scientifically accurate and conveys a clear-cut message, highlighting the efficacy of immune checkpoint inhibitors in low PD-L1–expressing patients with advanced esophageal squamous cell carcinoma (ESCC). It may be of global interest to readers and will have significant contribution to the journal.

A minor comment:

Recently, Wu et al[1] conducted a post hoc analysis of JUPITER-06 and a meta-analysis based on randomized controlled trials to determine the efficacy of immunochemotherapy in subgroup of advanced ESCC whose tumors exhibit low PD-L1 expression. The results of their study support the superiority of adding PD-1 antibody to chemotherapy as a first-line treatment for patients with advanced ESCC with low PD-L1 expression (TPS < 1% or combined positive score < 10). So, I suggest review their work. A relevant discussion would be helpful for readers.

Reference:

[1] J Clin Oncol. 2023 Mar 20;41(9):1735-1746. doi: 10.1200/JCO.22.01490.

### Response:

Thank you for the valuable suggestion and providing the reference. We agree that discussing the findings of this paper will enrich our editorial. We have reviewed the mentioned study and incorporated a relevant discussion, ensuring to highlight the significance of the findings and how they correlate with our work, while duly citing the source.

### Changes in the text:

We added a paragraph discussing the findings of this paper, please see lines 115-125, page 3. We also cited the paper under the references.